IP Library Granted Patent US 8,338,416
Granted Patent B2
US 8,338,416 · App. 11/687,565 · Granted Dec 25, 2012

Indole derivatives as inhibitors of histone deacetylase

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,338,416
App. No.
11/687,565
Granted
Dec 25, 2012
Kind
B2
Abstract

Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.

Claims (68)

1. A 1,3-disubstituted-1H-indole-6-carboxylic acid hydroxyamide compound, wherein the substituent at the 1-position is —X 2 —R 2 and the substituent at the 3-position is R 3 , wherein:

X 2 is a substituted or unsubstituted group selected from among C 2 -C 6 alkynylene, C 1 -C 6 heteroalkylene; —C(═O)—, and —C(═O)—C 1 -C 6 alkylene;

R 2 is a substituted or unsubstituted group selected from among aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;

where if R 2 is substituted, then each substituent on R 2 is selected from among hydrogen, halogen, —CN, —NO 2 , —S(═O) 2 NH 2 , —CO 2 H, —CO 2 R 10 , —C(═O)R 11 , —S—R 11 , —S(═O)—R 11 , —S(═O) 2 —R 11 , —NR 10 C(═O)—R 11 , —C(═O)N(R 10 ) 2 , —S(═O) 2 N(R 10 ) 2 , —OC(═O)N(R 10 ) 2 , —NR 10 C(═O)O—R 11 , —OC(═O)O—R 11 , —NHC(═O)NH—R 11 , —OC(═O)—R 11 ; —N(R 10 ) 2 , substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 2 -C 6 alkenyl, substituted or unsubstituted C 2 -C 6 alkynyl, substituted or unsubstituted C 1 -C 6 alkoxy, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;

R 10 is hydrogen, or a substituted or unsubstituted group selected from among C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 3 -C 8 cycloalkyl, C 2 -C 8 heterocycloalkyl, aryl, and heteroaryl;

R 11 is a substituted or unsubstituted group selected from among C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 2 -C 8 heterocycloalkyl, aryl, and heteroaryl;

R 3 is hydrogen, halogen, substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 2 -C 6 alkenyl, substituted or unsubstituted C 2 -C 6 alkynyl, substituted or unsubstituted C 1 -C 6 alkoxy, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted phenyl, or —X 6 —R 6 ;

X 6 is a C 1 -C 6 alkylene, C 1 -C 6 -fluoroalkylene, C 2 -C 6 alkenylene, C 2 -C 6 heteroalkylene;

R 6 is hydrogen, halogen, —CN, hydroxy, amino, C 1 -C 6 alkylamino, di(C 1 -C 6 alkyl)amino, C 1 -C 6 alkoxy, C 3 -C 8 cycloalkyl, C 2 -C 8 heterocycloalkyl, phenyl, heteroaryl, or —X 7 —R 7

X 7 is a bond, —O—, —S—, —S(═O)—, —S(═O) 2 —, —NR a —, —C(═O)—, —C(═O)O—, —OC(═O)—, —NHC(═O)—, —C(═O)NR a —, —S(═O) 2 NR a —, —NHS(═O) 2 —, —OC(═O)NR a —, —NHC(═O)O—, —OC(═O)O—, or —NHC(═O)NR a —;

R 7 is hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 1 -C 6 heteroalkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, cycloalkylalkyl, C 2 -C 8 heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,

R a is selected from among hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, hydroxy, C 1 -C 6 alkoxy, C 1 -C 6 fluoroalkoxy, C 1 -C 6 heteroalkyl; or

R a and R 7 together with the N atom to which they are attached form a 5-, 6-, or 7-membered heterocycloalkyl;

or pharmaceutically acceptable salt, pharmaceutically acceptable N-oxide, or

pharmaceutically acceptable prodrug thereof.

2. The compound of claim 1 , wherein:

R 2 is a substituted or unsubstituted group selected from among phenyl, naphthyl, monocyclic heteroaryl, bicyclic heteroaryl, C 3 -C 8 cycloalkyl, monocyclic heterocycloalkyl, and bicyclic heterocycloalkyl.

3. The compound of claim 2 , wherein:

R 2 is a substituted or unsubstituted group selected from among phenyl, naphthyl, (monocyclic heteroaryl containing 0-2 N atoms, 0-10 atoms, and 0-1 S atoms), (bicyclic heteroaryl containing 0-2 N atoms, 0-10 atoms, and 0-1 S atoms), C 3 -C 8 cycloalkyl, monocyclic heterocycloalkyl containing 0-2 N atoms, and bicyclic heterocycloalkyl containing 0-2 N atoms;

where if R 2 is substituted, then each substituent on R 2 is selected from among hydrogen, halogen, —CN, —NO 2 , —S(═O) 2 NH 2 , —CO 2 H, —CO 2 R 10 , —C(═O)R 11 , —S—R 11 , —S(═O)—R 11 , —S(═O) 2 11 , —NR 10 C(═O)—R 11 , —C(═O)N(R 10 ) 2 , —S(═O) 2 N(R 10 ) 2 , —NR 10 S(═O) 2 —R 11 , —OC(═O)—R 11 ; —N(R 10 ) 2 , substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 2 -C 6 alkenyl, substituted or unsubstituted C 1 -C 6 alkoxy, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;

R 10 is hydrogen, or a substituted or unsubstituted group selected from among C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 3 -C 8 cycloalkyl, C 2 -C 8 heterocycloalkyl, phenyl, and heteroaryl;

R 11 is a substituted or unsubstituted group selected from among C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 2 -C 8 heterocycloalkyl, phenyl, and hetero aryl.

4. The compound of claim 3 , wherein:

R 2 is a substituted or unsubstituted group selected from among phenyl, naphthyl, (monocyclic heteroaryl containing 0-2 N atoms, 0-10 atoms, and 0-1 S atoms), (bicyclic heteroaryl containing 0-2 N atoms, 0-10 atoms, and 0-1 S atoms), C 3 -C 8 cycloalkyl;

where if R 2 is substituted, then each substituent on R 2 is selected from among hydrogen, halogen, —CN, —NO 2 , —S(═O) 2 NH 2 , —CO 2 H, —CO 2 R 10 , —C(═O)R 11 , —S—R 11 , —S(˜O)—R 11 , —S(═O) 2 —R 11 , —NR 10 C(═O)—R 11 , —C(═O)N(R 10 ) 2 , —S(═O) 2 N(R 10 ) 2 , —NR 10 S(═O) 2 —R 11 , —OC(═O)—R 11 ; —N(R 10 ) 2 , substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 2 -C 6 alkenyl, substituted or unsubstituted C 1 -C 6 alkoxy, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;

R 10 is hydrogen, or a substituted or unsubstituted group selected from among C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, and phenyl;

R 11 is a substituted or unsubstituted group selected from among C 1 -C 6 alkyl, and phenyl.

5. The compound of claim 4 , wherein:

R 3 is hydrogen, halogen, substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 2 -C 6 alkenyl, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted phenyl, or —X 6 —R 6 ;

X 6 is a C 1 -C 6 alkylene, C 1 -C 6 -fluoroalkylene, C 2 -C 6 alkenylene, or C 2 -C 6 heteroalkylene;

R 6 is hydrogen, halogen, —CN, hydroxy, amino, C 1 -C 6 alkylamino, di(C 1 -C 6 alkyl)amino, C 1 -C 6 alkoxy, C 3 -C 8 cycloalkyl, C 2 -C 8 heterocycloalkyl, phenyl, heteroaryl, or —X 7 —R 7

X 7 is a bond, —O—, —S—, —S(═O)—, —S(═O) 2 —, —NR a —, —C(═O)—, —C(═O)O—, —OC(═O)—, —NHC(═O)—, —C(═O)NR a —, —S(═O) 2 NR a —, —NHS(═O) 2 —, —OC(═O)NR a —, —NHC(═O)O—, —OC(═O)O—, —NHC(═O)NR a —;

R 7 is hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 1 -C 6 heteroalkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, cycloalkylalkyl, C 2 -C 8 heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,

R a is selected from among hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, hydroxy, C 1 -C 6 alkoxy, C 1 -C 6 heteroalkyl; or

R a and R 7 together with the N atom to which they are attached form a 5-, 6-, or 7-membered heterocycloalkyl.

6. The compound of claim 5 , wherein:

R 3 is hydrogen, halogen, substituted or unsubstituted C 1 -C 6 alkyl, or —X 6 —R 6 .

7. The compound of claim 6 , wherein:

X 6 is C 1 -C 6 alkylene;

R 6 is hydrogen, halogen, —CN, hydroxy, amino, C 1 -C 6 alkylamino, di(C 1 -C 6 alkyl)amino, C 1 -C 6 alkoxy, C 3 -C 8 cycloalkyl, C 2 -C 8 heterocycloalkyl containing 0-2 N atoms, phenyl, heteroaryl containing 0-2 N atoms, or —X 7 —R 7 ;

X 7 is a bond, —O—, —S—, —S(═O)—, —S(═O) 2 —, —NR a —, —C(═O)—, —C(═O)O—, —OC(═O)—, —NHC(═O)—, —C(═O)NR a —, —S(═O) 2 NR a —, —NHS(═O) 2 —;

R 7 is hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 1 -C 6 heteroalkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, cycloalkylalkyl, C 2 -C 8 heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,

R a is selected from among hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, hydroxy, C 6 alkoxy, C 1 -C 6 heteroalkyl; or

R a and R 7 together with the N atom to which they are attached form a 5-, 6-, or 7-membered heterocycloalkyl.

8. The claim of claim 7 , wherein:

R 6 is —X 7 —R 7 .

9. The compound of claim 8 , wherein:

X 7 is a bond, —O—, —S—, —S(═O)—, —S(═O) 2 —, —NR a —, or —C(═O)—.

10. The compound of claim 9 , wherein:

R 7 is hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 1 -C 6 heteroalkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, cycloalkylalkyl, C 2 -C 8 heterocycloalkyl, heterocycloalkylalkyl, phenyl, phenylC 1 -C 4 alkyl, heteroaryl, heteroarylC 1 -C 4 alkyl,

R a is selected from among hydrogen, C 1 -C 6 alkyl, hydroxy, C 1 -C 6 alkoxy, C 1 -C 6 heteroalkyl; or

R a and R 7 together with the N atom to which they are attached form a 5-, or 6-membered heterocycloalkyl.

11. The compound of claim 10 , wherein:

X 7 is a bond, —O—, or —NR a —.

12. A compound selected from among:

1 (N-methylsulfonyl-3-aminobenzyl)-1H-indole-6-carboxylic acid hydroxyamide (Compound 28); 3-(Dimethylaminomethyl)-1-(4-methoxybenzyl)-1H-indole-6-carboxylic acid hydroxyamide (Compound 29); 3-(N-Morpholinomethyl)-1-(4-methoxybenzyl)-1H-indole-6-carboxylic acid hydroxyamide (Compound 30); 3-(N-Pyrrolidinomethyl)-1-(4-methoxybenzyl)-1H-indole-6-carboxylic acid hydroxyamide (Compound 31); 3-(N-Benzylaminomethyl)-1-(4-methoxybenzyl)-1H-indole-6-carboxylic acid hydroxyamide (Compound 32); and 3-(Ethyl)-1-(4-methoxybenzyl)-1H-indole-6-carboxylic acid hydroxyamide (Compound 33).

13. The compound of claim 1 , wherein the compound is a selective histone deacetylase 8 (HDAC8) inhibitor.

14. The compound of claim 13 , wherein the selective HDAC8 inhibitor has an IC 50 for histone deacetylase 8 activity that is at least 10 fold lower than the IC 50 of the selective HDAC8 inhibitor for activity of histone deacetylase 1, histone deacetylase 2, histone deacetylase 3, histone deacetylase 6, histone deacetylase 10, or histone deacetylase 11.

15. A pharmaceutical composition comprising a compound, pharmaceutically acceptable salt, pharmaceutically acceptable N-oxide, or pharmaceutically acceptable prodrug, of claim 1 and a pharmaceutically acceptable diluent, excipient or binder.

16. The compound of claim 1 , wherein R 2 is a substituted group selected from among aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;

where each substituent on R 2 is selected from —S(═O) 2 NH 2 , —CO 2 H, —CO 2 R 10 , —C(═O)R 11 , —S—R 11 , —S(═O)—R 11 , —S(═O) 2 —R 11 , —NR 10 C(═O)—R 11 , —C(═O)N(R 10 ) 2 , —S(═O) 2 N(R 10 ) 2 , —NR 10 S(═O) 2 —R 11 , —OC(═O)N(R 10 ) 2 , —NR 10 C(═O)O—R 11 , —OC(═O)O—R 11 , —NHC(═O)NH—R 11 , —OC(═O)—R 11 ; —N(R 10 ) 2 , C 1 -C 6 -fluoroalkyl substituted or unsubstituted C 2 -C 6 alkynyl, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.

17. The compound of claim 16 , wherein R 3 is halogen, substituted or unsubstituted C 2 -C 6 alkynyl, substituted C 1 -C 6 alkoxy, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted phenyl, or —X 6 —R 6 .

18. The compound of claim 17 , wherein X 6 is a C 2 -C 6 heteroalkylene.

19. The compound of claim 17 , wherein R 6 is hydrogen, hydroxy, C 3 -C 8 cycloalkyl, C 2 -C 8 heterocycloalkyl, phenyl, heteroaryl, or —X 7 —R 7 wherein

X 7 is, —O—, —S—, —S(═O)—, —S(═O) 2 —, —NR a —, —C(═O)—, —C(═O)O—, —OC(═O)—, —NHC(═O)—, —C(═O)NR a —, —S(═O) 2 NR a —, —NHS(═O) 2 —, —OC(═O)NR a —, —NHC(═O)O—, —OC(═O)O—, or —NHC(═O)NR a —;

R 7 is hydrogen, C 1 -C 6 heteroalkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, cycloalkylalkyl, C 2 -C 8 heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,

R a is C 1 -C 6 -fluoroalkoxy or C 1 -C 6 heteroalkyl; or

R a and R 7 together with the N atom to which they are attached form a 5-, 6-, or 7-membered heterocycloalkyl.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA PREVIOUSLY RECORDED ON REEL 036126 FRAME 0377. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Recorded May 17, 2016
From: OXFORD AMHERST CORPORATION; PHARMACYCLICS, INC.
To: PHARMACYCLICS, INC.
Reel/Frame 038722/0776 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA PREVIOUSLY RECORDED ON REEL 036126 FRAME 0398. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER AND CHANGE OF NAME. Recorded May 17, 2016
From: PHARMACYCLICS, INC.; OXFORD AMHERST LLC
To: PHARMACYCLICS LLC
Reel/Frame 038722/0849 →
MERGER Recorded Jul 16, 2015
From: OXFORD AMHERST CORPORATION
To: PHARMACYCLICS, INC.
Reel/Frame 036126/0377 →
MERGER AND CHANGE OF NAME Recorded Jul 16, 2015
From: PHARMACYCLICS, INC.; OXFORD AMHERST LLC
To: PHARMACYCLICS LLC
Reel/Frame 036126/0398 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2007
From: BUGGY, JOSEPH J.; BALASUBRAMANIAN, SRIRAM; VERNER, ERIK; TAI, VINCENT W.F.; LEE, CHANG-SUN
To: PHARMACYLICS, INC.
Reel/Frame 019539/0151 →